Hernandez et al. reported that baseline VAP-1/SSAO activity was associated with the incidence of HT, and treatment with a VAP-1//SSAO inhibitor prevented adverse effects caused by delayed t-PA administration in a rat model [95]. The gene discussed is AOC3; the disease is hematocrit.